Products developed by Theratechnologies target unmet medical needs in commercially attractive specialty markets.

NEWS AND EVENTS

News

News for year:
  • November 13, 2008

    Theratechnologies: Last patient treated in the extension phase of the confirmatory study testing tesamorelin in HIV-associated lipodystrophy More...

  • November 6, 2008

    Theratechnologies presents additional results from its tesamorelin Phase 3 studies at the 10th International workshop on adverse drug reactions and lipodystrophy in HIV More...

  • October 29, 2008

    Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States More...

  • October 28, 2008

    Notice of Conference Call & Media Advisory More...

  • October 9, 2008

    Theratechnologies Announces Financial Results and Highlights for the Third Quarter 2008 More...

  • September 30, 2008

    Theratechnologies to present at BioContact Québec More...

  • September 18, 2008

    Theratechnologies to present at UBS Global Life Sciences Conference More...

  • September 2, 2008

    Theratechnologies announces publication in AIDS More...

  • August 4, 2008

    Theratechnologies Reports on Positive Body Image Parameters at the International AIDS Conference More...

  • July 31, 2008

    Theratechnologies Presents at Both BMO and Canaccord Adams Conferences and Comments on Strategic Review More...

  • July 9, 2008

    Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2008 More...

  • June 20, 2008

    Theratechnologies Comments on Current Market Activity More...

  • June 18, 2008

    THERATECHNOLOGIES REPORTS POSITIVE 26-WEEK RESULTS FOR ITS SECOND TESAMORELIN PHASE 3 TRIAL More...

  • June 17, 2008

    Notice of Conference Call & Media Advisory More...

  • May 15, 2008

    Theratechnologies explores tesamorelin in growth hormone deficient abdominal obesity More...

  • May 14, 2008

    Notice of Conference Call & Media Advisory More...

  • May 12, 2008

    Theratechnologies and PDC Biotech GmbH sign license agreement for family of peptides for Preterm Labour and Primary Dysmenorrhea programs More...

  • May 5, 2008

    Theratechnologies to present at BioFinance 2008 conference More...

  • April 17, 2008

    Theratechnologies receives the 2008 Genesis Innovation Award More...

  • April 14, 2008

    Theratechnologies: Last patient treated in the confirmatory study testing tesamorelin in HIV-associated lipodystrophy More...

  • March 25, 2008

    Theratechnologies announces financial results and highlights of the first quarter 2008 More...

  • March 24, 2008

    Theratechnologies: Annual General Meeting of Shareholders More...

  • February 13, 2008

    Theratechnologies closes $29,750,000 financing More...

  • February 6, 2008

    Theratechnologies presents additional results from its tesamorelin 52-week Phase 3 study at the Conference on Retroviruses and Opportunistic Infections More...

  • January 31, 2008

    Theratechnologies announces common share offering More...

  • January 29, 2008

    Theratechnologies announces review of strategic alternatives and filing of preliminary base shelf prospectus for up to $35 million equity financing More...

  • January 23, 2008

    2007: A year of major accomplishments for Theratechnologies More...

  • January 8, 2008

    Theratechnologies extends patent protection for tesamorelin in the treatment of HIV-associated lipodystrophy More...

 

This website contains all press releases issued by Theratechnologies between 2002 and 2005. To obtain prior press releases, please visit SEDAR’s website at: www.sedar.com.

SUBSCRIBE TO OUR EMAIL LIST

Email address
Email address confirmation

ALTERNATIVE TO THE EMAIL LIST

We invite you to subscribe to our site using a RSS feed. This technology keeps you posted on new developments announced on our website.

The RSS feed does not use your email, thus:

  • No spam
  • No viruses
  • Easy to unsubscribe

Find out more...